Conversational AI helper goes live for healthcare consumers in Colorado

Colorado’s UCHealth system has extended the reach of “Livi,” an AI-powered virtual assistant it introduced early this year, from its website to patients’ smart speakers.

The service is so far only available to consumers with Amazon’s Alexa on hand, but UCHealth plans to adapt it for those using Google Assistant, according to an item published by the institution’s news division.

A video demonstration posted with the article shows a spoken request for help with a cut finger.

Within seconds, Livi—who sounds like Alexa—recommends a visit to a nearby UCHealth urgent-care center.

The institution’s chief marketing and experience officer, Manny Rodriguez, says this new adoption of conversational AI grew out of UCHealth’s focus on pleasing patients with more convenience and easier accessibility.

“Patients want information at their fingertips—whether that be via phone, computer or even smart speakers—and we want to be able to give them what they need as quickly and easily as possible,” Rodriguez says.

The healthcare system, which operates more than 150 facilities, is now working to integrate Livi with its EHR and its mobile app. The latter will let patients ask about upcoming appointments, latest test results and so on.

UCHealth’s CIO, Steve Hess, notes the Livi technology is HIPAA-compliant but does not diagnose any conditions or replace conversations with a doctor.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.